Inside Information / Other news releases

Ikonisys closes capital increase through a private placement to further accelerate its commercial development

Paris, June 3, 2024 – 8:45 pm CEST - Ikonisys SA (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the “Issuer”), today announces that it raised €150k, by way of a private placement with a private investor, in order to strengthen its financial resources and further accelerate its development.

The net proceeds of this issue, amounting to €150k, should provide the Issuer with additional resources to support its commercial development, by financing its working capital needs and extend its financial visibility. The new funds will also enable the Issuer to accelerate the integration of Hospitex^[1] and further implement their commercial strategy, by expanding their offer in Europe and at a later stage in the USA.

Legal terms of the Capital Increase

The implementation of this capital increase, carried out with cancellation of shareholders' subscription rights through a private placement, was approved by the Board of Directors of the Issuer at its meeting held on May 30, 2024 (the "Capital Increase"). 

The new shares will be issued on the basis of the 8^th resolution of the Issuer's shareholders' meeting held on June 28, 2023. The settlement-delivery of the new shares will take place on June 4, 2024.

The Capital Increase did not require the approval of a notice (“prospectus”) by the Autorité des marchés financiers (the “AMF”).

Main terms of the Capital Increase

The Issuer has issued a total of 100,000 new ordinary shares, with a par value of €0.5 each, to the investor, pursuant to article L. 411-2 1° of the French Monetary and Financial Code, in accordance with the 8^th resolution passed by its Annual General Meeting on June 28, 2023. 

The issuance price of the new shares issued under the Capital Increase, equal to €1.5 per share, represents a premium of approximately 3% on the Ikonisys share price at the close of May 31, 2024.

Impact of the transaction in terms of liquidity risk management and financing horizon

As at June 30, 2023, and as mentioned in the half-year financial statements published on October 31, 2023, the Issuer's consolidated cash position amounted to €66k. 

Thank to the Capital Increase and the previously secured financing facility, the Company will be in a position to meet its financing needs for more than 12 months.

Impact of the Capital Increase on a shareholder holding 1% of the capital

On the basis of the 10,451,424  shares outstanding, the impact on the shareholding of a shareholder holding 1% of the Issuer's capital prior to the transaction is as follows: 

¹ Dilution takes into account the exercise of all outstanding dilutive instruments likely to result in the issuance of a maximum indicative number of 397,043 new shares. 

Capital breakdown before and after completion of the Capital Increase

Before the Capital Increase:

*Holding company of the CEO, Mario Crovetto

After the Capital Increase:

*Holding company of the CEO, Mario Crovetto

Risk factors related to the Issuer

Detailed information about the Issuer, including its business, financial information, results, outlook and related risk factors, is contained in the 2022 annual financial report for the financial year ended December 31, 2022, published on April 29, 2023, and in the half-year report 2023, published on October 31, 2023. This document, together with other regulated information and all the Issuer's press releases, is available on the Issuer's website (www.ikonisys-finance.com).

About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® and Ikoniscope20max® platforms, fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to www.ikonisys-finance.com

Contacts

Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.